If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Medical Affairs » Health Outcomes
Download FREE Excerpt
11 Info Graphics
32 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Demonstrating a drug’s value proposition and its potential in real-world practice will maximize business and clinical success. The Health Economics Outcomes Research function is a key player in generating value-oriented outcomes data, but it needs to effectively collaborate with other groups to leverage the information. Likewise, it's critical to correctly time the collection of outcomes data for products in development so that it can optimize the launch of approved new products.
This study illustrates the strategies for effective health outcomes data communication and utilization and how HEOR collaborates with key internal stakeholders. The research also outlines the launch investment timeline for HEOR activities during new product development.
Segmentation based on two areas: Geographic responsibility and HEOR reporting structure
Fifty-four medical leaders from 40 top life-science companies were engaged through a benchmarking survey.
Pharmaceutical; Consumer Products; Health Care; Biotech; Biopharmaceutical; Clinical Research; Laboratories; Manufacturing; Diagnostic; Medical Device; Communications
AbbVie; Astellas; Merck Serono; Novartis; Sanofi; Boehringer Ingelheim; Eisai; Pfizer; Merck Sharp & Dohme; Bayer; Lundbeck; CSL Behring; Ipsen; Novo Nordisk; Takeda Pharmaceuticals; Alkem; Smith & Nephew; Galderma; Seqirus; Vifor Pharma; Daiichi Sankyo; Brii Biosciences; Foundation Medicine; Seattle Genetics; La Jolla Pharmaceutical; Alexion Pharmaceuticals; Sun Pharmaceutical; Grünenthal; BioCryst Pharmaceuticals; Harmony Biosciences; BioMarin; Luminex Corporation; Dova Pharmaceuticals; Karyopharm Therapeutics; Paratek Pharmaceuticals; Pharming; Bioventus; Nucleus Global; Greenwich Biosciences; Pacira Biosciences
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.